ArticleMedicina (Kaunas, Lithuania)2026

First-Line Palbociclib/Letrozole Versus Ribociclib/Letrozole in Postmenopausal HR-Positive/HER2-Negative Metastatic Breast Cancer: A Retrospective Real-World Study and an Exploratory Composite Clinical-Inflammatory Risk Score.

Mert Tohumcuoğlu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.